BCL2 and prostate carcinoma: A recent study found upregulation of BCL2 and WEE1 kinase in small cell neuroendocrine (SCN) cancers, and combining Navitoclax and the WEE1 inhibitor AZ-1775 was synergistic against SCN prostate cancer patient-derived xenografts [67].